Ann: $6.6 million Placement to advance clinical trial pipeline, page-63

Have a read of that announcement again. It basically states that due to trouble with the dosing method, the trial is stopped until it can be redesigned. That was the lead drug then.

That's pretty crushing stuff.

That drug cost CHM over $10 million to get the right to take it to the clinic. It was a huge cash draw. It's not performing in the time frame planned with results hoped for was huge for the company. That $10 million being paid off, as well as the other two drugs, has been a huge help to quarterly cash burn.

Until yesterday, CHM has been going quarter to quarter, trying to find a cash pathway. Hence, the number of CRs. It seemed like that pathway had been sorted prior to the suspension last year ( my guess only) and then fell apart. Maybe that was the non dilutive money?

Yesterday, although savage to the SOI, has removed a lot of that finance problem.

I am sorry this investment didn't go as well as it should have.